Inclusion Criteria:

- Histologically proven unresectable or recurrent adenocarcinoma of stomach and
gastroesophageal junction

- Patients without prior systemic treatment. Patients who completed postoperative
adjuvant chemotherapy (and radiotherapy) more than 180 days before may be enrolled

- Peritoneal metastasis and/or cancer cells on peritoneal cytology

- Age >21 years

- Eastern Cooperative Oncology Group performance status 0-2

- Adequate bone marrow function (neutrophil count >1500/mm3, hemoglobin >8.0 g/dl and
platelet count >100 000/mm3)

- Adequate liver function (bilirubin, AST (aspartate aminotransferase)/ALT (alanine
aminotransferase) within upper limit of normal)

- Adequate renal function (serum creatinine within the upper limit of normal)

- Expected survival >3 months

- Able to take orally

- Able to understand and the willingness to sign a written informed consent document

- The effects of proposed regimen on the developing human fetus at the recommended
therapeutic dose are unknown. For this reason and because antitumor agents as well
as other therapeutic agents used in this trial are known to be teratogenic, women of
child-bearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately.

Exclusion Criteria:

- Metastasis to distant organ sites (such as the liver, lungs or bone)

- When trastuzumab is considered for palliative chemotherapy

- Known allergy to taxane, fluoropyrimidine or oxaliplatin

- Previous malignancy other than gastric cancer diagnosed in the last 5 years except
for basal cell carcinoma of skin or preinvasive cancer of cervix

- Patients with reproductive potential who refuse to use an adequate means of
contraception (including male patients)

- Significant disease or conditions which, in the investigator's opinion, would exclude
patient from the study

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant or lactating female